Wistar Institute Breakthrough: Novel HIV Vaccine Induces Neutralizing Antibodies After Single Shot

Scientists at The Wistar Institute have announced a significant breakthrough: an experimental HIV vaccine candidate that induced neutralizing antibodies against HIV after just a single immunization in nonhuman primates. This unprecedented outcome marks a new milestone in the field. The groundbreaking research was spearheaded by Amelia Escolano, Ph.D., an assistant professor at Wistar's Vaccine and Immunotherapy Center.

This outcome had not been observed previously in the field.

Engineering the Vaccine Candidate

The core of this innovative approach centers on an engineered HIV envelope protein named WIN332. Researchers specifically modified a region known as the V3-glycan epitope by removing the N332-glycan sugar. This design choice challenges previous conventional wisdom, as past efforts to engineer HIV vaccines had preserved this sugar, believing it essential for antibodies targeting this region to bind effectively.

A Simplified Vaccination Protocol

The experimental vaccine demonstrated immediate promise. A single injection of WIN332 induced low but detectable neutralization against HIV within three weeks. A subsequent second injection, utilizing a related immunogen, led to a significant increase in neutralization levels.

This approach could potentially shorten and simplify HIV vaccination protocols, possibly requiring three injections instead of seven to ten, according to Ignacio Relano-Rodriguez, Ph.D., a co-author of the study.

Unveiling New Antibody Types

Beyond the simplified protocol, the removal of the N332-glycan yielded a crucial discovery in immunology. It facilitated the identification of two distinct types of HIV-neutralizing antibodies that target the V3-glycan region. Type I antibodies necessitate the N332 sugar for effective binding, while Type II antibodies—a newly identified class—do not.

This discovery may broaden the options for developing HIV vaccines that offer protection against various HIV strains.

Next Steps Towards Clinical Trials

These promising results have already attracted considerable attention from global health organizations, positioning the candidate for potential advancement into human clinical trials. Further preclinical evaluations are currently underway, alongside ongoing efforts to design immunogens for an even more shortened vaccination series.